Gilteritinib Fumarate

DRUG2 trials

Sponsors

Children's Oncology Group, City of Hope Medical Center

Conditions

Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia

Phase 1

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

WithdrawnNCT04655391

City of Hope Medical CenterRecurrent Acute Myeloid Leukemia

Start: 2022-06-25End: 2023-12-15Updated: 2022-06-09

Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecruitingNCT04293562

Children's Oncology GroupAcute Myeloid Leukemia

Start: 2020-07-21End: 2029-06-30Target: 1186Updated: 2026-02-24

Related Papers

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Blood2025-11-03

Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report

Frontiers in Cardiovascular Medicine2024-06-144 citations

Structural variants involving <i>MLLT10</i> fusion are associated with adverse outcomes in pediatric acute myeloid leukemia

Blood Advances2024-02-027 citations

Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy

Frontiers in Cardiovascular Medicine2023-12-016 citations

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Blood2023-11-021 citations

<i>Crebbp</i> Alterations Are Associated with a Poor Prognosis in <i>De Novo</i> AML

Blood2021-11-057 citations

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions

HemaSphere2021-06-0112 citations